摘要
目的探讨齐拉西酮注射液与氟哌啶醇治疗精神分裂症急性期的疗效及不良反应的差异。方法用Meta分析对6项齐拉西酮注射液与氟哌啶醇治疗精神分裂症急性期对照研究的文章进行再分析,评价其合并效应量大小和综合显著性检验。结果齐拉西酮注射液治疗前后的自身对照,合并效应量d=2.14,95%CI(1.90,2.39),综合显著性检验χ2=17.07,P<0.01,提示齐拉西酮注射液治疗精神分裂症急性期前后症状学变化有非常显著性差异,效应极强。齐拉西酮注射液与氟哌啶醇在第24小时末和治疗72h后的组间比较,分别为y合并=-0.10,95%CI(-0.77,0.57,χ2=0.29,P>0.05;y合并=-0.17,95%CI(-0.71,0.37),χ2=0.62,P>0.05,差异无统计学意义,提示两组疗效相当。齐拉西酮注射液的不良反应显著少于氟哌啶醇。结论齐拉西酮注射液与氟哌啶醇疗效相当,不良反应少。
Objective To study the difference of efficacy and side e ffect of ziprasidon injection and haloperidol injectio in the treatment of schizophrenia during acutephase. Methods 6 comparative studies of ziprasidon injection and haloperidol injectio in the treatment of schizophrenia during acutephase were analyzed by meta-ananlysis. Results The significant difference in change of symptom afte and r before treatment by duloxetine was found, d=2.14, 95% CI（1.90,2.39）,χ2=17.07,P0.01.Comparison between ziprasidon injection and haloperidol injectio at 24 hours treatment and at the end of each trial showed that y合并=-0.10,95% CI（-0.77, 0.57,χ2=0.29,P0.05;y合并=-0.17,95% CI（-0.71, 0.37）,χ2=0.62,P0.05, which revealed that there was no singnificant difference between ziprasidon injection and haloperidol injectio with respect to the clinical efficacy,with significantly less adverse effects compared with haloperidol injectio. Conclusion Ziprasidon injection has a similar clinical effecacy with haloperidol injectio,less adverse effects.
出处
《中国实用医药》
2013年第16期31-32,共2页
China Practical Medicine
